Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc1b299fd17b1c2beddf8c20f946442a |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-627 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
filingDate |
2018-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d700577748ae26f004923d406181edb5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61c56c6e8067fed0eff266f7592ad933 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fc16abc7c506c2a458dcfdcb978ca50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2bff45ff7723ef1dcf08d26bbcb10ca |
publicationDate |
2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3641803-A2 |
titleOfInvention |
Personalized vaccine |
abstract |
The present invention generally relates to a personalized anti-cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptides or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable carrier, as well as the use of said personalized cancer vaccine to treat a cancerous subject in need. A specific embodiment relates to a method of providing such a vaccine or composition comprising an identifying step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, preferably all coding regions of the genome (exome), c) sequencing said target regions (eg exome) from said extracted DNAs, and d) identifying a or a number of tumor-specific mutations by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administering such a personalized cancer vaccine. The invention is of particular interest in the field of personalized immunotherapy, in particular for stimulating the immune response of T lymphocytes. |
priorityDate |
2017-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |